Showing posts with label Margaret Chan. Show all posts
Showing posts with label Margaret Chan. Show all posts

Wednesday, September 05, 2012

Socialized Healthcare 8: Anita Wagner on UHC and Medicines

* This is the continuation of my discussion on the AIM lectures last Monday, September 03.  Here is the earlier discussion, Socialized Healthcare 7: Degnan and Wagner on ICIUM and UHC.

Dr. Anita Wagner presented a paper on Universal Coverage or Universal HealthCare (UHC) as used here in the Philippines or other countries. The three questions on expanding healthcare coverage are: (a) extend to non-contributors to the fund, the very poor? (b) expand HC services? and (c) reduce cost and mandatory fees?


I believe in UHC, that everyone, from the poor to the rich, young and old, should have one form of health insurance that can cover both outpatient and hospitalization services. But I do not believe that it is only the government, or mainly the government, that should provide such service. I believe there is a big role for both corporate and civil society provision of healthcare at various levels: community or village, work place and offices, schools and universities. Just give the people various options and choices where and what kind of HC coverage at different price packages would satisfy their personal and household needs.

The medicines aspect of HC. The share of the "pharmerging" (emerging and industrializing economies' consumption of pharmaceutical products) markets to global medicines spending is rising, from only 14 percent of total world demand in 2006, to 20 percent last year, and projected to grow to 30 percent by 2016.

Table below shows that almost 30 percent of total HC spending in low-income countries goes to medicines alone, and only 18.2 percent for high incomes ones.



I think the main reason why the poor has a high percentage of their household healthcare spending  that goes to medicines is because they have no health insurance for outpatient services other than those offered by the nearby government clinic or hospital. For instance, when they have a headache or prolonged fever or bad stomach, among the first things they do is to buy medicines that they see are heavily advertised in tv, radio, billboards and newspapers or magazines. Or those that are recommended by their neighbors, family members and friends. They do not go to private clinics and physicians because physician consultation fee alone would be about the equivalent to one or two-day/s work. And if the physician would order a diagnostic test, the cost would soar further. So the solution is not to see a doctor and just self-medicate. So spending for professional fee and for diagnostic test/s is zero or near zero, the denominator is low, and that raises the share of medicines (the numerator) to total household health spending.

Below, the same story, that spending for medicines dominate the total household healthcare spending. And I offer the same explanation above why this is so. Low chart, same medicines, different cost. Naturally. Why? 


The same way that the price of soda (Coke or Pepsi, etc.) would vary from an ordinary variety (or "sari-sari") store to convenience store to a cheap restaurant to a fine dining resto to a hotel. A bottle of an 8 oz soda for instance can range from P8 to P70 depending on where one would buy the soft drink.

The price of medicines for the same molecule, same dosage, from the same manufacturer, can vary from one drugstore or pharmacy to another. A drugstore in a low-rental place, no air-conditioner, no licensed pharmacist, not paying multiple taxes, can sell medicines at very low price. A drugstore or pharmacy in a high-end mall, fully air-conditioned, has several licensed pharmacists, and complies with various/multiple taxes and regulatory fees, will have to pass on those costs to the price of their medicines. Hospitals will have additional costs to charge when they dispense medicines to their confined patients.

Tuesday, April 24, 2012

RUM 4: Dealing with Drug-Resistant Diseases

Cases of illness that are drug-resistant are a growing problem worldwide. That's because diseases -- like people, animals, insects, bacteria, plants, trees, all other living matter and organisms -- are evolving and mutating. The appearance of "superbugs" or the killer diseases that do not respond even to the strongest medicines was also noted by some sectors recently.

Do we need more government presence -- via the WHO, other foreign aid, DOH, local governments, other government agencies -- in dealing with this problem?

I have an ambivalent position on this issue. That's because I recognize that there is room for government assistance and intervention in dealing with infectious and communicable diseases, as well as pediatric diseases. But I also insist that better personal care, more personal responsibility in preventing the spread of those infectious diseases -- like washing hands more often, covering the mouth when coughing, eating healthy diet, drinking lots of water, having sufficient rest and sleep, observing rational use of medicines (RUM),  etc. -- is also important.

I am posting four articles by Reiner Gloor, the Executive Director of the Pharmaceutical and Healthcare Association of the Philippines (PHAP, http://phap.org.ph/) about this subject. These papers were posted in his weekly column in BusinessWorld (http://www.bworldonline.com/) on days indicator. He is more knowledgeable about this subject than me because they know what are those old and new or emerging diseases, as well as the existing supply of medicines, both innovator and generics, in dealing with this problem. These four papers are:

1. The fight vs. drug-resistant diseases, March 23, 2012
2. Appreciating antibiotics, April 15, 2011
3. Global action vs. AMR, April 08, 2011
4. World Health Day and drug resistance, April 01, 2011.

A bit long, enjoy reading.
---------


(1) The fight vs drug-resistant diseases

Reiner W. Gloor
March 23, 2012

http://www.bworldonline.com/weekender/content.php?id=48829


Often driven by economics and politics, humans have always been on the move. The International Organization for Migration reported that there were about 214 million global migrants in 2010 and their number could reach 405 million by year 2050.

But aside from people, drug-resistant pathogens are also constantly on the move. In her address at the conference on combating anti-microbial resistance (AMR): time for action in Copenhagen last week, World Health Organization (WHO) Director-General Margaret Chan reminded us that these pathogens are “notorious globe-trotters”.

The WHO chief said that drug-resistant microorganisms travel well in infected air passengers and through global trade in food.

And instead of providing cure for patients, some hospitals have also become hotbeds for highly resistant pathogens. Chan noted that the growth of medical tourism has expedited the international spread of hospital-acquired infections that are frequently resistant to multiple drugs.

Apart from increased mortality and substantial financial burden, AMR has consequences far beyond the patient, their families and the health sector. AMR can also leave a damaging aftermath on international travel and trade resulting from the cross-border spread of drug-resistant infections.